Bibliographies thématiques / Daclatasvir

Sommaire

  1. Articles de revues
  2. Thèses
  3. Livres
  4. Chapitres de livres
  5. Actes de conférences
  6. Rapports d'organisations

Littérature scientifique sur le sujet « Daclatasvir »

Auteur : Grafiati
Publié le 9 mars 2023
Mis à jour le 31 juillet 2025

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Daclatasvir ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Daclatasvir"

1

Sacramento, Carolina Q., Natalia Fintelman-Rodrigues, Jairo R. Temerozo, et al. "In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19." Journal of Antimicrobial Chemotherapy 76, no. 7 (2021): 1874–85. http://dx.doi.org/10.1093/jac/dkab072.

Texte intégral
Résumé :
Abstract Background Current approaches of drug repurposing against COVID-19 have not proven overwhelmingly successful and the SARS-CoV-2 pandemic continues to cause major global mortality. SARS-CoV-2 nsp12, its RNA polymerase, shares homology in the nucleotide uptake channel with the HCV orthologue enzyme NS5B. Besides, HCV enzyme NS5A has pleiotropic activities, such as RNA binding, that are shared with various SARS-CoV-2 proteins. Thus, anti-HCV NS5B and NS5A inhibitors, like sofosbuvir and daclatasvir, respectively, could be endowed with anti-SARS-CoV-2 activity. Methods SARS-CoV-2-infected
Styles APA, Harvard, Vancouver, ISO, etc.
2

Smith, Michael A., Randolph E. Regal, and Rima A. Mohammad. "Daclatasvir." Annals of Pharmacotherapy 50, no. 1 (2015): 39–46. http://dx.doi.org/10.1177/1060028015610342.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

CH., V. S. Gautam* N. Harika V. Balaji V. Srinivas Prasad. "METHOD DEVELOPMENT AND VALIDATION OF DACLATASVIR IN BULK & PHARMACEUTICAL DOSAGE FORM BY UV-VISIBLE SPECTROPHOTOMETRY." INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES 05, no. 03 (2018): 1980–85. https://doi.org/10.5281/zenodo.1213232.

Texte intégral
Résumé :
Objective: The objective of the present work is to develop a simple, efficient, and reproducible spectrophotometric method for the quantitative estimation of hepatitis-C drug - Daclatasvir in active pharmaceutical ingredient(API) form and in pharmaceutical dosage form Methods: The developed ultraviolet spectrophotometric method for the quantitative estimation of hepatitis-C drugs - Daclatasvir based on measurement of absorption at a wavelength maximum (λmax) of 317 nm using methanol as solvent. Results: The method was validated in terms of, precision, linearity, accuracy, and robustness
Styles APA, Harvard, Vancouver, ISO, etc.
4

Ravindra S Morey, Ganesh G Tapadiya, and Manisha V Doud. "Development and validation of stability indicating HPTLC method for estimation of Daclatasvir Dihydrochloride in pharmaceutical dosage form." World Journal of Advanced Research and Reviews 23, no. 2 (2024): 2470–78. http://dx.doi.org/10.30574/wjarr.2024.23.2.2569.

Texte intégral
Résumé :
A high-performance thin-layer chromatographic method was developed and validated for estimation of Daclatasvir Dihydrochloride in pharmaceutical dosage form. The proposed method was applied successfully to the pharmaceutical analysis of the recently approved dosage form of Daclatasvir Dihydrochloride which is available in market as a brand name of ‘NALDAC 60’ tablets. The drugs were satisfactorily show peak with RF 0.38 for Daclatasvir Dihydrochloride. Method was validated according to the ICH guidelines. The calibration plot was linear between 50-300 ng per band for Daclatasvir Dihydrochlorid
Styles APA, Harvard, Vancouver, ISO, etc.
5

Ravindra, S. Morey, G. Tapadiya Ganesh, and V. Doud Manisha. "Development and validation of stability indicating HPTLC method for estimation of Daclatasvir Dihydrochloride in pharmaceutical dosage form." World Journal of Advanced Research and Reviews 23, no. 2 (2024): 2470–78. https://doi.org/10.5281/zenodo.14891592.

Texte intégral
Résumé :
A high-performance thin-layer chromatographic method was developed and validated for estimation of Daclatasvir Dihydrochloride in pharmaceutical dosage form. The proposed method was applied successfully to the pharmaceutical analysis of the recently approved dosage form of Daclatasvir Dihydrochloride which is available in market as a brand name of ‘NALDAC 60’ tablets. The drugs were satisfactorily show peak with RF 0.38 for Daclatasvir Dihydrochloride. Method was validated according to the ICH guidelines. The calibration plot was linear between 50-300 ng per band for Daclatasvir Di
Styles APA, Harvard, Vancouver, ISO, etc.
6

Reviriego, C. "Daclatasvir dihydrochloride." Drugs of the Future 36, no. 10 (2011): 735. http://dx.doi.org/10.1358/dof.2011.036.10.1703570.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Reviriego, C. "Daclatasvir dihydrochloride." Drugs of the Future 36, no. 10 (2011): 735. http://dx.doi.org/10.1358/dof.2011.36.10.1703570.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Chakravarthy, V. Ashok, Sailaja Bbv, and Praveen Kumar A. "METHOD DEVELOPMENT AND VALIDATION OF ULTRAVIOLET-VISIBLE SPECTROSCOPIC METHOD FOR THE ESTIMATION OF HEPATITIS-C DRUGS - DACLATASVIR AND SOFOSBUVIR IN ACTIVE PHARMACEUTICAL INGREDIENT FORM." Asian Journal of Pharmaceutical and Clinical Research 9, no. 9 (2016): 61. http://dx.doi.org/10.22159/ajpcr.2016.v9s3.14616.

Texte intégral
Résumé :
ABSTRACTObjective: The objective of the present work is to develop a simple, efficient, and reproducible spectrophotometric method for the quantitativeestimation of hepatitis-C drugs - Daclatasvir and Sofosbuvir in its active pharmaceutical ingredient (API) form.Methods: The developed ultraviolet spectrophotometric method for the quantitative estimation of hepatitis-C drugs - Daclatasvir and Sofosbuvir isbased on measurement of absorption at a wavelength maximum (λmax) of 317 and 261 nm using methanol as solvent.Results: The method was validated in terms of specificity, precision, linearity, a
Styles APA, Harvard, Vancouver, ISO, etc.
9

SHULPEKOVA, Y. O., N. V. SHULPEKOVA, M. C. SEMENISTAYA, A. A. USANOVA, and C. S. PAVLOV. "TREATMENT OF HCV INFECTION BY A COMBINATION OF SOFOSBUVIR AND DACLATASVIR." Medical Council, no. 4 (May 26, 2017): 36–41. http://dx.doi.org/10.21518/2079-701x-2017-4-36-41.

Texte intégral
Résumé :
The purpose of the review is to evaluate the efficacy and safety of using pangenotypic combination «of Sofosbuvir/Daclatasvir» — the direct action antiviral drugs in the treatment of chronic HCV infection at different stages of liver damage.Main provisions: Sofosbuvir is the antisense nucleotide, inhibiting RNA-dependent RNA-polymerase NS5B, this drug has earned a reputation as one of the strongest anti-replication drugs, including when there is interferon resistance. Daclatasvir is a powerful non-nucleotide inhibitor of NS5А protein, catalyzing formation of replicative complexes. Both compone
Styles APA, Harvard, Vancouver, ISO, etc.
10

Ahmad Ather, Ch Adnan, Mariyam Nawaz, Sohail Bashir Sulehria, Saadia Chaudary, Zara Mehmood, and Maria Rehman. ""TREATMENT SUCCESS OF SOFOSBUVIR AND DACLATSVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS OFHEPATITIS C VIRUS"." Journal of Akhtar Saeed Medical & Dental College 05, no. 02 (2023): 90–96. https://doi.org/10.51127/jamdcv5i2oa05.

Texte intégral
Résumé :
Background:To compare the frequency of responders achieving SVR12 after taking sofosbuvir and daclatasvir with vs without ribavirin.Material and Methods:Total 180 patients meeting inclusion criteria were enrolled in the studyfromDepartment of Medicine, Government Teaching Hospital Shahdara, Lahore.This randomized controlled trial was conducted fromMarch 25, 2021,to September 24, 2021.Treatment naive cases were given tablet sofosbuvir & daclatasvir for 12 weeks. Treatment-experienced and naive with cirrhosis were given ribavirin based on their body weight along with sofosbuvir and daclatasv
Styles APA, Harvard, Vancouver, ISO, etc.
Plus de sources

Thèses sur le sujet "Daclatasvir"

1

BARROS, Luciana Tavares de Carvalho. "Avaliação da eficácia e segurança do daclatasvir e sofosbuvir versus alfapeginterferona 2A no tratamento da hepatite C crônica." Universidade Federal de Pernambuco, 2016. https://repositorio.ufpe.br/handle/123456789/24772.

Texte intégral
Résumé :
Submitted by Alice Araujo (alice.caraujo@ufpe.br) on 2018-06-05T18:24:22Z No. of bitstreams: 1 DISSERTAÇÃO Luciana Tavares de Carvalho Barros.pdf: 978217 bytes, checksum: 9bbd97bc0d108d6999496e25f30b47df (MD5)<br>Made available in DSpace on 2018-06-05T18:24:22Z (GMT). No. of bitstreams: 1 DISSERTAÇÃO Luciana Tavares de Carvalho Barros.pdf: 978217 bytes, checksum: 9bbd97bc0d108d6999496e25f30b47df (MD5) Previous issue date: 2016-06-09<br>A Hepatite C representa um grande impacto na saúde pública em todo o mundo. Interfere na vida dos portadores de HCV, na sociedade, no sistema de saúde e n
Styles APA, Harvard, Vancouver, ISO, etc.
2

Grimm, Christian [Verfasser], Robert [Gutachter] Tampé, and Christoph [Gutachter] Welsch. "Charakterisierung des Lipidbindungsverhaltens und der Proteinfaltung von HCV NS5A unter Einfluss des NS5A-Inhibitors Daclatasvir / Christian Grimm ; Gutachter: Robert Tampé, Christoph Welsch." Frankfurt am Main : Universitätsbibliothek Johann Christian Senckenberg, 2021. http://d-nb.info/1239730276/34.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Jarek, Nayara Almeida de Assis. "Análise de custo-efetividade do tratamento precoce da hepatite viral C crônica com simeprevir, daclatasvir e sofosbuvir sob a perspectiva do Sistema Único de Saúde." reponame:Repositório Institucional da UFPR, 2017. http://hdl.handle.net/1884/53663.

Texte intégral
Résumé :
Orientador : Prof. Dr. Roberto Pontarolo<br>Coorientadora : Drª. Inajara Rotta<br>Dissertação (mestrado) - Universidade Federal do Paraná, Setor de Ciências da Saúde, Programa de Pós-Graduação em Ciências Farmacêuticas. Defesa: Curitiba, 22/09/2017<br>Inclui referências : f. 83-93<br>Resumo: A hepatite viral C crônica é causada pelo vírus da hepatite C (VHC) e os indivíduos são considerados curados após atingir a resposta virológica sustentada (RVS). Porém, os elevados custos dificultam o acesso às terapias disponíveis. Dados os recursos limitados, a inserção de novas terapias deve ter sua via
Styles APA, Harvard, Vancouver, ISO, etc.
4

REGHELLIN, VERONICA. "Studies on the mechanism of action of antiviral agents targeting the replication complex of hepatitis c virus." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2014. http://hdl.handle.net/10281/52708.

Texte intégral
Résumé :
At the moment, several companies are studying the clinical potential of different all-oral combinations of direct-acting antivirals in ongoing studies. The most promising interferon-free combination therapies that are on the horizon include linear or cyclic NS3/4A protease inhibitors, nucleoside as well as non-nucleoside NS5B polymerase inhibitors , and NS5A inhibitors. DAAs that target NS3/4A (protease) and NS5B (RNA-dependent RNA polymerase) inhibit the enzymatic activity of these proteins. NS5A replication complex inhibitors will likely form a component of future interferon-free dru
Styles APA, Harvard, Vancouver, ISO, etc.
5

Chen, Hsuan-Yi, and 陳宣怡. "All-Oral Direct-Acting Agent Daclatasvir Plus Asunaprevir for Chronic Genotype 1b Hepatitis C Virus Infection Patients: Real-World Experience of Virologic Response and Side Effects." Thesis, 2016. http://ndltd.ncl.edu.tw/handle/2m99sr.

Texte intégral
Résumé :
碩士<br>中山醫學大學<br>醫學研究所<br>104<br>Introduction: All-oral direct-acting agent dual therapy with Daclatasvir plus Asunaprevir (DCV+ASV) achieved high sustained virological responses (SVR) in genotype 1b (GT-1b) HCV patients in the HALLMARK-DUAL1 study and Phase 3 Japanese study2,3. DCV + ASV is approved in several countries including Taiwan in March, 2016, Japan, Korea, and Latin America, Eastern Europe. In this study, real-world experience of DCV+ASV dual therapy in HCV GT-1b patients was reported. Purpose: To evaluate the efficacy and safety of DCV+ASV therapy in GT-1b HCV infected Taiwanese pat
Styles APA, Harvard, Vancouver, ISO, etc.

Livres sur le sujet "Daclatasvir"

1

Blokdijk, G. J. Daclatasvir Dihydrochloride; A Clear and Concise Reference. CreateSpace Independent Publishing Platform, 2018.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.

Chapitres de livres sur le sujet "Daclatasvir"

1

Belema, Makonen, Shawn K. Pack, and Nicholas A. Meanwell. "Daclatasvir (Daklinza): The First-in-Class HCV NS5A Replication Complex Inhibitor." In Innovative Drug Synthesis. John Wiley & Sons, Inc, 2015. http://dx.doi.org/10.1002/9781118819951.ch3.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Mitsui, Fukiko, C. Nelson Hayes, Fumitaka Suzuki, and Kazuaki Chayama. "The Efficacy of Daclatasvir Plus Asunaprevir Combination Therapy with Chronic Hepatitis." In Hepatitis C Virus Treatment. Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-10-2416-0_3.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Meanwell, Nicholas A., and Makonen Belema. "The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex." In Topics in Medicinal Chemistry. Springer International Publishing, 2019. http://dx.doi.org/10.1007/7355_2018_47.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

"DAKLINZA (Daclatasvir)." In Antibiotics Manual. John Wiley & Sons, Ltd, 2017. http://dx.doi.org/10.1002/9781119220787.ch50.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Belema, Makonen, Steven M. Schnittman, and Nicholas A. Meanwell. "Case History: The Discovery of the First Hepatitis C Virus NS5A Replication Complex Inhibitor Daclatasvir (Daklinza™)." In Medicinal Chemistry Reviews. Medicinal Chemistry Division of the American Chemical Society, 2016. http://dx.doi.org/10.29200/acsmedchemrev-v51.ch22.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

VOLKWEIS, J. G., A. C. C. SANCHES, O. D. BOEIRA JUNIOR, and J. A. D. HORVATH. "AVALIAÇÃO DO USO E ANÁLISE DE CUSTOS DOS MEDICAMENTOS SOFOSBUVIR, SIMEPREVIR, DACLATASVIR PARA TRATAMENTO DA HEPATITE VIRAL CRÔNICA TIPO C DO COMPONENTE ESPECIALIZADO DA ASSISTÊNCIA FARMACÊUTICA NO MUNICÍPIO DE CASCAVEL - PR." In Diálogos entre Enfermagem e Farmácia: – Volume 1. Dialética, 2023. http://dx.doi.org/10.48021/978-65-270-0772-2-c4.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.

Actes de conférences sur le sujet "Daclatasvir"

1

Nimie, Hemlata M., and Minakshi N. Deodhar. "Method Development and Force Degradation Study for Daclatasvir Using LC-MS/MS." In 2020 Advances in Science and Engineering Technology International Conferences (ASET). IEEE, 2020. http://dx.doi.org/10.1109/aset48392.2020.9118229.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Pajin, R. Madera, R. Asensi Diez, L. Yunquera Romero, JC Del Rio Valencia, and I. Muñoz Castillo. "DI-044 Effectiveness of the combination sofosbuvir and daclatasvir for the treatment of hepatitis C virus infection." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.291.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.

Rapports d'organisations sur le sujet "Daclatasvir"

1

Hung, Hsuan-Yu, Hui-Hsiung Lai, Hui-Chuan Lin, and Chung-Yu Chen. Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C: A network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.7.0055.

Texte intégral
Résumé :
Review question / Objective: P: ("Hepatitis C"[Mesh] AND "Hepacivirus"[Mesh] AND "Hepatitis C, Chronic”[Mesh]) I: (direct acting antiviral OR asunaprevir OR boceprevir OR daclatasvir OR dasabuvir OR elbasvir OR glecaprevir OR grazoprevir OR ledipasvir OR ombitasvir OR paritaprevir OR pibrentasvir OR simeprevir OR sofosbuvir OR telaprevir OR velpatasvir OR voxilaprevir) C: placebo O: ( "Cholesterol, VLDL"[Mesh] OR "Cholesterol, LDL"[Mesh] OR "Cholesterol, HDL"[Mesh] OR "Dyslipidemias"[Mesh] OR "lipoprotein cholesterol ester, human" [Supplementary Concept] OR "lipoprotein cholesterol" [Supplemen
Styles APA, Harvard, Vancouver, ISO, etc.
Vous pouvez également être intéressé par les bibliographies sur le sujet « Daclatasvir » pour d’autres types de sources :
Articles de revues
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!

Vers la bibliographie